ATE466937T1 - Verfahren zum nachweis von leberkrebs, diagnostikum für leberkrebs sowie heilmittel gegen krebs - Google Patents

Verfahren zum nachweis von leberkrebs, diagnostikum für leberkrebs sowie heilmittel gegen krebs

Info

Publication number
ATE466937T1
ATE466937T1 AT04819413T AT04819413T ATE466937T1 AT E466937 T1 ATE466937 T1 AT E466937T1 AT 04819413 T AT04819413 T AT 04819413T AT 04819413 T AT04819413 T AT 04819413T AT E466937 T1 ATE466937 T1 AT E466937T1
Authority
AT
Austria
Prior art keywords
cancer
liver cancer
dlk
detecting liver
antibody
Prior art date
Application number
AT04819413T
Other languages
English (en)
Inventor
Koji Nakamura
Hiroko Anzai
Hiroyuki Yanai
Atsushi Miyajima
Original Assignee
Kanagawa Kagaku Gijutsu Akad
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kanagawa Kagaku Gijutsu Akad filed Critical Kanagawa Kagaku Gijutsu Akad
Application granted granted Critical
Publication of ATE466937T1 publication Critical patent/ATE466937T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303Liver or Pancreas
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57525Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734Complement-dependent cytotoxicity [CDC]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/91Transferases (2.)
    • G01N2333/912Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205Phosphotransferases in general
    • G01N2333/9121Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT04819413T 2003-11-28 2004-11-25 Verfahren zum nachweis von leberkrebs, diagnostikum für leberkrebs sowie heilmittel gegen krebs ATE466937T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2003399331 2003-11-28
JP2003401585 2003-12-01
JP2003423237 2003-12-19
PCT/JP2004/017499 WO2005052156A1 (ja) 2003-11-28 2004-11-25 肝癌の検出方法及び肝癌診断薬並びに癌治療薬

Publications (1)

Publication Number Publication Date
ATE466937T1 true ATE466937T1 (de) 2010-05-15

Family

ID=34636972

Family Applications (2)

Application Number Title Priority Date Filing Date
AT10003331T ATE546527T1 (de) 2003-11-28 2004-11-25 Verfahren zum nachweis von leberkrebs, diagnose auf leberkrebs und heilmittel gegen krebs
AT04819413T ATE466937T1 (de) 2003-11-28 2004-11-25 Verfahren zum nachweis von leberkrebs, diagnostikum für leberkrebs sowie heilmittel gegen krebs

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT10003331T ATE546527T1 (de) 2003-11-28 2004-11-25 Verfahren zum nachweis von leberkrebs, diagnose auf leberkrebs und heilmittel gegen krebs

Country Status (8)

Country Link
US (2) US20080112956A1 (de)
EP (2) EP1702982B1 (de)
JP (1) JP4695982B2 (de)
AT (2) ATE546527T1 (de)
CA (1) CA2552553C (de)
DE (1) DE602004027085D1 (de)
ES (2) ES2345493T3 (de)
WO (1) WO2005052156A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5219827B2 (ja) * 2006-11-10 2013-06-26 株式会社リブテック invivoで抗腫瘍活性を有する抗ヒトDlk−1抗体
EP2275537B1 (de) * 2008-03-17 2014-12-24 Livtech Inc. Anti-mensch-dlk-1-antikörper mit antikörperaktivität in vivo
KR100964193B1 (ko) * 2009-04-17 2010-06-16 씨비에스바이오사이언스 주식회사 간암 예후 마커
EA201500220A1 (ru) 2010-05-17 2015-10-30 Ливтех, Инк. Антитело против trop-2 человека, обладающее противоопухолевой активностью in vivo
EP2412792A1 (de) 2010-07-29 2012-02-01 The Procter & Gamble Company Flüssige Reinigungsmittelzusammensetzung
WO2012138102A2 (ko) * 2011-04-04 2012-10-11 한국생명공학연구원 Dlk1 특이적 인간 항체 및 이를 포함하는 약학적 조성물
WO2012138100A2 (ko) * 2011-04-04 2012-10-11 한국생명공학연구원 Dlk1 세포 외 수용성 도메인을 포함하는 액티빈 수용체 타입 2b 억제제
CN102778566B (zh) * 2011-05-07 2016-01-13 上海市肿瘤研究所 Dlk1在肝癌诊断及预后判断中的应用
US9427464B2 (en) 2011-11-22 2016-08-30 Chiome Bioscience Inc. Anti-human TROP-2 antibody having an antitumor activity in vivo
CN104704119B (zh) 2012-10-03 2017-09-05 凯奥目生物科学株式会社 在体内具有抗肿瘤活性的抗人Dlk‑1抗体
PH12016502249B1 (en) 2014-05-15 2023-12-13 Eisai R&D Man Co Ltd Pladienolide pyridine compounds and methods of use
BR112018009995B1 (pt) 2015-11-18 2024-04-30 Eisai R&D Management Co., Ltd Forma cristalina, composição farmacêutica, e, uso da forma cristalina
CN110031629B (zh) * 2018-01-11 2020-08-18 上海交通大学 检测人血清dlk1蛋白的elisa试剂盒及其用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU677623B2 (en) * 1992-12-11 1997-05-01 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Delta-like gene expressed in neuroendocrine tumors
US20030185815A1 (en) * 2001-04-03 2003-10-02 Muralidhara Padigaru Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use
ATE410688T1 (de) * 2001-05-16 2008-10-15 Kanagawa Kagaku Gijutsu Akad Verfahren zum nachweis und zur trennung undifferenzierter leberzellen mit dlk
US7189507B2 (en) * 2001-06-18 2007-03-13 Pdl Biopharma, Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
EP1594447A2 (de) * 2002-10-02 2005-11-16 Genentech, Inc. Zusammensetzungen und verfahren f r die tumor- diagnose und behandlung
WO2004048938A2 (en) * 2002-11-26 2004-06-10 Protein Design Labs, Inc. Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators

Also Published As

Publication number Publication date
EP2204448A1 (de) 2010-07-07
EP2204448B1 (de) 2012-02-22
US20100151503A1 (en) 2010-06-17
JP4695982B2 (ja) 2011-06-08
CA2552553A1 (en) 2005-06-09
EP1702982B1 (de) 2010-05-05
ES2382987T3 (es) 2012-06-15
EP1702982A4 (de) 2007-04-25
US20080112956A1 (en) 2008-05-15
DE602004027085D1 (de) 2010-06-17
WO2005052156A1 (ja) 2005-06-09
JPWO2005052156A1 (ja) 2007-12-06
CA2552553C (en) 2015-01-06
EP1702982A1 (de) 2006-09-20
ES2345493T3 (es) 2010-09-24
ATE546527T1 (de) 2012-03-15

Similar Documents

Publication Publication Date Title
ATE466937T1 (de) Verfahren zum nachweis von leberkrebs, diagnostikum für leberkrebs sowie heilmittel gegen krebs
DE602005013225D1 (de) Aptamer-nanopartikelkonjugate und verwendungsverfahren zur detektion von zielanalyten
WO2006126008A3 (en) Improved immunoassay methods
WO2010033371A3 (en) Molecular markers for lung and colorectal carcinomas
EE05650B1 (et) Antikehade radioaktiivse m„rgistamise komplekt ja seostamistest
WO2007075675A3 (en) High precision code plates and geophones
WO2008111464A1 (ja) スプライシング異常を指標とする抗ガン剤の作用検定方法
Früh et al. Strain field self-diagnostic poly (dimethylsiloxane) elastomers
ATE541054T1 (de) Bio-barcode erkennung für zielmoleküle
DE602005013998D1 (de) Verfahren und reagenzien zur erkennung von melanomen
WO2012050365A3 (ko) 교모세포종의 진단 또는 예후 예측용 바이오 마커 및 그 용도
EP2074427A4 (de) Diagnostik-biomolekül(e)
WO2006002243A3 (en) Methods of oligosaccharide profiling for the detection of cancer
ATE462803T1 (de) Kit und verfahren zum nachweis von urothelkarzinom
ATE414701T1 (de) Fluoreszenzsonden zur verwendung bei einem bindungsassay auf proteinkinaseinhibitoren
WO2007092664A3 (en) Blocker reagent for reduction of heterophile interferences
DE60329861D1 (de) Neue, auf der antigen-antikörper-reaktion beruhende sondenplatte sowie reagenzienkit und verfahren mit verwendung der sondenplatte
ATE408832T1 (de) Verfahren zum nachweis von blutzell-antigenen und gegen diese gerichtete antikörper
ATE529746T1 (de) Zusammensetzung und verfahren zum nachweis von analyten über eine polymerisierungsbasierte signalverstärkung
WO2009016718A1 (ja) 診断薬及びそれを用いた診断方法
ATE396404T1 (de) Verfahren zum nachweis biologischer moleküle
CY1109461T1 (el) Βελτιωμενες μεθοδοι ανοσολογικου προσδιορισμου
DE60139314D1 (de) Verfahren zum prüfen von mit wt1-verbundenen krankheiten
DE602005013430D1 (de) Verwendung von asc als marker für kolorektalkarzinome
WO2009008489A1 (ja) 抗体リポソーム

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties